Structural basis of cyclic oligoadenylate degradation by ancillary Type III CRISPR-Cas ring nucleases
- PMID: 34850143
- PMCID: PMC8643638
- DOI: 10.1093/nar/gkab1130
Structural basis of cyclic oligoadenylate degradation by ancillary Type III CRISPR-Cas ring nucleases
Abstract
Type III CRISPR-Cas effector systems detect foreign RNA triggering DNA and RNA cleavage and synthesizing cyclic oligoadenylate molecules (cA) in their Cas10 subunit. cAs act as a second messenger activating auxiliary nucleases, leading to an indiscriminate RNA degradation that can end in cell dormancy or death. Standalone ring nucleases are CRISPR ancillary proteins which downregulate the strong immune response of Type III systems by degrading cA. These enzymes contain a CRISPR-associated Rossman-fold (CARF) domain, which binds and cleaves the cA molecule. Here, we present the structures of the standalone ring nuclease from Sulfolobus islandicus (Sis) 0811 in its apo and post-catalytic states. This enzyme is composed by a N-terminal CARF and a C-terminal wHTH domain. Sis0811 presents a phosphodiester hydrolysis metal-independent mechanism, which cleaves cA4 rings to generate linear adenylate species, thus reducing the levels of the second messenger and switching off the cell antiviral state. The structural and biochemical analysis revealed the coupling of a cork-screw conformational change with the positioning of key catalytic residues to proceed with cA4 phosphodiester hydrolysis in a non-concerted manner.
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.
Figures






References
-
- Barrangou R., Fremaux C., Deveau H., Richards M., Boyaval P., Moineau S., Romero D.A., Horvath P.. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007; 315:1709. - PubMed
-
- Mohanraju P., Makarova K.S., Zetsche B., Zhang F., Koonin E.v, van der Oost J.. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems. Science. 2016; 353:aad5147. - PubMed
-
- Amitai G., Sorek R.. CRISPR–Cas adaptation: insights into the mechanism of action. Nat. Rev. Microbiol. 2016; 14:67–76. - PubMed
-
- Jackson S.A., McKenzie R.E., Fagerlund R.D., Kieper S.N., Fineran P.C., Brouns S.J.J.. CRISPR-Cas: adapting to change. Science. 2017; 356:eaal5056. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources